it's going to require some quick-rear guard actions by material holder to prevent this transfer of value to the bidder. The CEO appears to be recommending this evaluation enthusiastically. I would have thought A$10 per share plus, given the top of cycle US$:A$ and what this means in terms of a US$ valuation. in other words, far too low in US$ terms. Moreover, even more difficult to accept when you consider the SOI consolidations/dilutions to date.
Ann: Mayne Pharma enters Scheme Implementation Deed with Cosette, page-132
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.30 |
Change
0.220(4.33%) |
Mkt cap ! $429.7M | |||
| Open | High | Low | Value | Volume |
| $5.15 | $5.32 | $5.10 | $1.369M | 263.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 12 | $5.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.30 | 11606 | 3 |
View Market Depth
| Last trade - 14.35pm 17/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |